About FGL
Mimics NCAM-mediated signaling via FGFR (fibroblast growth factor receptor) activation. Stimulates downstream Erk1/2 and PLCγ pathways. Promotes long-term potentiation (LTP) and synaptogenesis.
FGL (EVYVVAENQQGKSKA) is a synthetic 15-amino-acid peptide derived from the fibronectin type III homology domain 2 of the neural cell adhesion molecule (NCAM), designed as a pharmacomimetic agonist of NCAM to activate FGFR-mediated neurotrophic signaling and mimic the synaptogenic and neuroprotective effects of NCAM receptor engagement in the central nervous system. FGL activates downstream FGFR signaling to promote synaptic plasticity, neuronal survival, and spatial learning in preclinical models; rodent studies have demonstrated cognitive-enhancing and anxiolytic effects in aged animals and in models of neurodegeneration, establishing a preclinical rationale for further investigation. No published human clinical trials, pharmacokinetic studies, or safety evaluations of FGL have been indexed in PubMed; the entirety of the evidence base consists of animal and in vitro studies, and no regulatory body has approved or evaluated FGL for any human indication. FGL has no FDA approval or regulatory approval in any jurisdiction; it is a research compound with a defined neurotrophic mechanism and an exclusively preclinical evidence base, and no clinical data exists to inform its pharmacokinetics, safety, or therapeutic utility in humans.
FGL Benefits & Research Areas
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
3 sources cited · 3 moderate
3 Cohorts
Quality and readability of patient information on robotic-assisted hip arthroplasty.
Ann Jt · 2026
# Summary Research found that online patient information about robotic-assisted hip arthroplasty demonstrated poor readability, with an average Flesch-Kincaid Grade Level (FGL) score of 11.6, indicating that comprehension requires at least a high school education level. This study demonstrated that the web-based information assessed had fair quality scores overall but showed significant deficiencies in adherence to credibility standards and accessibility for general patient populations.
A Peptide Inhibitor of Lymphocyte Activation Gene-3 Interaction with Fibrinogen-like Protein 1 Synergizes with Programmed Death-Ligand 1 Blockade to Restore T Cell Activity and Inhibit Tumor Growth.
Biomater Res · 2026
# Summary Research found that a peptide inhibitor (LAG3pep-2) that blocks the interaction between LAG-3 and fibrinogen-like protein 1 (FGL-1) restores T cell activity and synergizes with PD-L1 blockade to enhance anti-tumor immunity. This study demonstrated that the combination approach significantly suppressed tumor growth in animal models while maintaining a favorable safety profile compared to either treatment alone.
Nanocavity-Based "Turn-Off" Plasmonic Metasurface Sensing Platform for the Detection of Trace Cadmium Ions in Complex Matrices.
ACS Sens · 2026
# Summary This study demonstrated a plasmonic metasurface sensing platform that uses nanocavity closure to detect trace cadmium ions with high sensitivity and specificity in complex biological samples. Researchers observed that cadmium binding triggers aptamer conformational changes that displace gold nanoparticles from the sensor surface, producing a measurable optical signal while effectively reducing false-positive results from nonspecific adsorption.
FGL Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy FGL — Providers & Availability
2 providersStay updated on verified FGL providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — FGL
FGL (EVYVVAENQQGKSKA) is a synthetic 15-amino-acid peptide derived from the fibronectin type III homology domain 2 of the neural cell adhesion molecule (NCAM), designed as a pharmacomimetic agonist of NCAM to activate FGFR-mediated neurotrophic signaling and mimic the synaptogenic and neuroprotective effects of NCAM receptor engagement in the central nervous system. FGL activates downstream FGFR signaling to promote synaptic plasticity, neuronal survival, and spatial learning in preclinical models; rodent studies have demonstrated cognitive-enhancing and anxiolytic effects in aged animals and in models of neurodegeneration, establishing a preclinical rationale for further investigation.
synaptic plasticity, memory enhancement, neuroprotection, LTP promotion.
Research on FGL primarily documents effects related to synaptic plasticity and memory enhancement and neuroprotection and LTP promotion. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for FGL include pregnant or nursing. This is educational information only — consult a qualified healthcare professional before use.
2 providers in the directory currently offer FGL.
# Summary Research found that online patient information about robotic-assisted hip arthroplasty demonstrated poor readability, with an average Flesch-Kincaid Grade Level (FGL) score of 11.6, indicating that comprehension requires at least a high school education level. This study demonstrated that the web-based information assessed had fair quality scores overall but showed significant deficiencies in adherence to credibility standards and accessibility for general patient populations.